Christian W. Freudiger
Research Subjects
Christian W. Freudiger has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Ion-Margineanu
Invenio Imaging
3 shared publications - David Reinecke
Department of General Neurosurgery, Center for Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
2 shared publications Lea Lough
GeneCentrix Inc
2 shared publications- Miles P. Mannas
Department of Urologic Sciences, University of British Columbia, Vancouver, Canada; Vancouver Prostate Centre, Mohseni Institute of Urologic Sciences, Vancouver, Canada
2 shared publications - Mingyu Sheng
Vancouver Prostate Center, University of British Columbia
2 shared publications - Niklas von Spreckelsen
Department of General Neurosurgery, Centre of Neurosurgery, Faculty of Medicine and University Hospital, University of Cologne, Kerpener Str. 62, 50937 Köln, Germany
2 shared publications
Latest Publications
- 10 June 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 220,p. e68083
Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, making early detection and advancements in precision medicine crucial for effective intervention and treatment. A standardized protocol is presented for utilizing stimulated Raman histology (SRH) with integrated artificial intelligence (AI) in prostate cancer detection, offering significant advancements over conventional histopathological methods. SRH provides these advancements by enhancing efficiency through near-real-time, label-free imaging of fresh, unstained tissues, thereby eliminating the delays associated with traditional biopsy analysis. By using stimulated Raman scattering (SRS) microscopy to detect the specific vibrational frequencies of CH2 bonds associated with lipids and CH3 bonds linked to proteins and DNA, cancerous and benign tissues in prostate biopsies can be differentiated. The AI model further enhances diagnostic precision, achieving 98.6% accuracy in identifying prostate cancer. The protocol outlines essential steps for sample preparation, imaging, and data analysis, facilitating improved biobanking processes and enabling downstream applications, such as transcriptomics and xenograft studies. This approach accelerates the diagnostic workflow and shows promise for intraoperative applications, potentially aiding surgeons in identifying positive margins intraoperatively. Additionally, the ability to re-scan and adjust cancer-to-tissue ratios allows for a more tailored analysis of biopsy samples, enhancing tumor detection in unprocessed tissues. Further research and validation are necessary for the widespread adoption of SRH in clinical practice.
- 10 June 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 220,p. e68083
Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, making early detection and advancements in precision medicine crucial for effective intervention and treatment. A standardized protocol is presented for utilizing stimulated Raman histology (SRH) with integrated artificial intelligence (AI) in prostate cancer detection, offering significant advancements over conventional histopathological methods. SRH provides these advancements by enhancing efficiency through near-real-time, label-free imaging of fresh, unstained tissues, thereby eliminating the delays associated with traditional biopsy analysis. By using stimulated Raman scattering (SRS) microscopy to detect the specific vibrational frequencies of CH2 bonds associated with lipids and CH3 bonds linked to proteins and DNA, cancerous and benign tissues in prostate biopsies can be differentiated. The AI model further enhances diagnostic precision, achieving 98.6% accuracy in identifying prostate cancer. The protocol outlines essential steps for sample preparation, imaging, and data analysis, facilitating improved biobanking processes and enabling downstream applications, such as transcriptomics and xenograft studies. This approach accelerates the diagnostic workflow and shows promise for intraoperative applications, potentially aiding surgeons in identifying positive margins intraoperatively. Additionally, the ability to re-scan and adjust cancer-to-tissue ratios allows for a more tailored analysis of biopsy samples, enhancing tumor detection in unprocessed tissues. Further research and validation are necessary for the widespread adoption of SRH in clinical practice.
- 10 June 2025
- Published by MyJove Corporation
- No. 220,p. e68083
JoVE Video Dataset
Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, making early detection and advancements in precision medicine crucial for effective intervention and treatment. A standardized protocol is presented for utilizing stimulated Raman histology (SRH) with integrated artificial intelligence (AI) in prostate cancer detection, offering significant advancements over conventional histopathological methods. SRH provides these advancements by enhancing efficiency through near-real-time, label-free imaging of fresh, unstained tissues, thereby eliminating the delays associated with traditional biopsy analysis. By using stimulated Raman scattering (SRS) microscopy to detect the specific vibrational frequencies of CH2 bonds associated with lipids and CH3 bonds linked to proteins and DNA, cancerous and benign tissues in prostate biopsies can be differentiated. The AI model further enhances diagnostic precision, achieving 98.6% accuracy in identifying prostate cancer. The protocol outlines essential steps for sample preparation, imaging, and data analysis, facilitating improved biobanking processes and enabling downstream applications, such as transcriptomics and xenograft studies. This approach accelerates the diagnostic workflow and shows promise for intraoperative applications, potentially aiding surgeons in identifying positive margins intraoperatively. Additionally, the ability to re-scan and adjust cancer-to-tissue ratios allows for a more tailored analysis of biopsy samples, enhancing tumor detection in unprocessed tissues. Further research and validation are necessary for the widespread adoption of SRH in clinical practice.
- 10 June 2025
- Published by MyJove Corporation
- No. 220,p. e68083
JoVE Video Dataset
Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, making early detection and advancements in precision medicine crucial for effective intervention and treatment. A standardized protocol is presented for utilizing stimulated Raman histology (SRH) with integrated artificial intelligence (AI) in prostate cancer detection, offering significant advancements over conventional histopathological methods. SRH provides these advancements by enhancing efficiency through near-real-time, label-free imaging of fresh, unstained tissues, thereby eliminating the delays associated with traditional biopsy analysis. By using stimulated Raman scattering (SRS) microscopy to detect the specific vibrational frequencies of CH2 bonds associated with lipids and CH3 bonds linked to proteins and DNA, cancerous and benign tissues in prostate biopsies can be differentiated. The AI model further enhances diagnostic precision, achieving 98.6% accuracy in identifying prostate cancer. The protocol outlines essential steps for sample preparation, imaging, and data analysis, facilitating improved biobanking processes and enabling downstream applications, such as transcriptomics and xenograft studies. This approach accelerates the diagnostic workflow and shows promise for intraoperative applications, potentially aiding surgeons in identifying positive margins intraoperatively. Additionally, the ability to re-scan and adjust cancer-to-tissue ratios allows for a more tailored analysis of biopsy samples, enhancing tumor detection in unprocessed tissues. Further research and validation are necessary for the widespread adoption of SRH in clinical practice.
- Top Cited Papers
- 23 March 2023
- Published by Springer Nature in Nature Medicine
- Vol. 29 (4) , 828-832
Artificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging
Molecular classification has transformed the management of brain tumors by enabling more accurate prognostication and personalized treatment. However, timely molecular diagnostic testing for patients with brain tumors is limited, complicating surgical and adjuvant treatment and obstructing clinical trial enrollment. In this study, we developed DeepGlioma, a rapid (n = 153) who underwent real-time SRH imaging, we demonstrate that DeepGlioma can predict the molecular alterations used by the World Health Organization to define the adult-type diffuse glioma taxonomy (IDH mutation, 1p19q co-deletion and ATRX mutation), achieving a mean molecular classification accuracy of 93.3 ± 1.6%. Our results represent how artificial intelligence and optical histology can be used to provide a rapid and scalable adjunct to wet lab methods for the molecular screening of patients with diffuse glioma.
- 23 March 2023
- Published by Springer Nature in Nature Medicine
- Vol. 29 (4) , 828-832
Top Cited PapersArtificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging
Molecular classification has transformed the management of brain tumors by enabling more accurate prognostication and personalized treatment. However, timely molecular diagnostic testing for patients with brain tumors is limited, complicating surgical and adjuvant treatment and obstructing clinical trial enrollment. In this study, we developed DeepGlioma, a rapid (n = 153) who underwent real-time SRH imaging, we demonstrate that DeepGlioma can predict the molecular alterations used by the World Health Organization to define the adult-type diffuse glioma taxonomy (IDH mutation, 1p19q co-deletion and ATRX mutation), achieving a mean molecular classification accuracy of 93.3 ± 1.6%. Our results represent how artificial intelligence and optical histology can be used to provide a rapid and scalable adjunct to wet lab methods for the molecular screening of patients with diffuse glioma.
- Open Access
- 6 August 2022
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 10 (1) , 1-13
Novel rapid intraoperative qualitative tumor detection by a residual convolutional neural network using label-free stimulated Raman scattering microscopy
Determining the presence of tumor in biopsies and the decision-making during resections is often dependent on intraoperative rapid frozen-section histopathology. Recently, stimulated Raman scattering microscopy has been introduced to rapidly generate digital hematoxylin-and-eosin-stained-like images (stimulated Raman histology) for intraoperative analysis. To enable intraoperative prediction of tumor presence, we aimed to develop a new deep residual convolutional neural network in an automated pipeline and tested its validity. In a monocentric prospective clinical study with 94 patients undergoing biopsy, brain or spinal tumor resection, Stimulated Raman histology images of intraoperative tissue samples were obtained using a fiber-laser-based stimulated Raman scattering microscope. A residual network was established and trained in ResNetV50 to predict three classes for each image: (1) tumor, (2) non-tumor, and (3) low-quality. The residual network was validated on images obtained in three small random areas within the tissue samples and were blindly independently reviewed by a neuropathologist as ground truth. 402 images derived from 132 tissue samples were analyzed representing the entire spectrum of neurooncological surgery. The automated workflow took in a mean of 240 s per case, and the residual network correctly classified tumor (305/326), non-tumorous tissue (49/67), and low-quality (6/9) images with an inter-rater agreement of 89.6% (κ = 0.671). An excellent internal consistency was found among the random areas with 90.2% (Cα = 0.942) accuracy. In conclusion, the novel stimulated Raman histology-based residual network can reliably detect the microscopic presence of tumor and differentiate from non-tumorous brain tissue in resection and biopsy samples within 4 min and may pave a promising way for an alternative rapid intraoperative histopathological decision-making tool.
- 6 August 2022
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 10 (1) , 1-13
Open AccessNovel rapid intraoperative qualitative tumor detection by a residual convolutional neural network using label-free stimulated Raman scattering microscopy
Determining the presence of tumor in biopsies and the decision-making during resections is often dependent on intraoperative rapid frozen-section histopathology. Recently, stimulated Raman scattering microscopy has been introduced to rapidly generate digital hematoxylin-and-eosin-stained-like images (stimulated Raman histology) for intraoperative analysis. To enable intraoperative prediction of tumor presence, we aimed to develop a new deep residual convolutional neural network in an automated pipeline and tested its validity. In a monocentric prospective clinical study with 94 patients undergoing biopsy, brain or spinal tumor resection, Stimulated Raman histology images of intraoperative tissue samples were obtained using a fiber-laser-based stimulated Raman scattering microscope. A residual network was established and trained in ResNetV50 to predict three classes for each image: (1) tumor, (2) non-tumor, and (3) low-quality. The residual network was validated on images obtained in three small random areas within the tissue samples and were blindly independently reviewed by a neuropathologist as ground truth. 402 images derived from 132 tissue samples were analyzed representing the entire spectrum of neurooncological surgery. The automated workflow took in a mean of 240 s per case, and the residual network correctly classified tumor (305/326), non-tumorous tissue (49/67), and low-quality (6/9) images with an inter-rater agreement of 89.6% (κ = 0.671). An excellent internal consistency was found among the random areas with 90.2% (Cα = 0.942) accuracy. In conclusion, the novel stimulated Raman histology-based residual network can reliably detect the microscopic presence of tumor and differentiate from non-tumorous brain tissue in resection and biopsy samples within 4 min and may pave a promising way for an alternative rapid intraoperative histopathological decision-making tool.